In the past decade, TNF-α inhibitors Humira (AbbVie) and Enbrel (Amgen), as well as Janssen’s IL-12/23 inhibitor Stelara, have been leading the U.S. psoriasis biologics market. However, the recent wave of U.S. approvals for novel psoriasis agents—Celgene’s Otezla (2014), Novartis’s Cosentyx (2015), Eli Lilly’s Taltz (2016), Valeant’s Siliq (2017), Janssen’s Tremfya (2017), and Sun Pharma’s Ilumya (2018)—is anticipated to substantially alter the market landscape. The Psoriasis Emerging Therapy series includes three waves that will track the awareness, trial, and use of Tremfya following its launch in July 2017 for the treatment of psoriasis. In addition, the series will examine physicians’ anticipation of future trends in psoriasis treatment, particularly Tremfya’s uptake, and assess Janssen’s promotional efforts.

Questions Answered:

  • What is the awareness of, familiarity with, and perceptions related to Tremfya among U.S. dermatologists?
  • According to prescribers, to which patients are they prescribing Tremfya, why are they prescribing Tremfya, and how satisfied are they with Tremfya?
  • How do prescribers and nonprescribers compare across key metrics?
  • How is the trial and adoption of Tremfya tracking compared with other recent product launches in the autoimmune market?

Product Description:

Emerging Therapies is a three-wave series based on primary research data collected at 1, 6, and 12 months postcommercial launch with U.S. physicians. The research captures physicians’ awareness, perceptions, and use of the launched product, as well as anticipated future trends. Insight is also provided on promotional efforts, prescriber and nonprescriber profiles, and benchmarking against other launched agents.

Table of contents

  • Psoriasis - Emerging Therapies - Tremfya Launch Tracking Wave 3 (US)

Author(s): Matthew W. Scutcher, MEng PhD; Yingdee Unhavaithaya

Matthew Scutcher is Therapy Leader for the Immune & Inflammatory research team at DRG.  

In this role, he leads a team of 13 Research Associates, Business Insights Analysts and Directors responsible for analyzing some of the largest and most dynamic markets in the pharmaceutical industry

He has been with DRG since 2009 and holds a Ph.D. from University College London and a Master’s degree in Chemical Engineering from Imperial College London.

Yingdee Unhavaithaya is a Business Insights Analyst on the Immune and Inflammatory Disorders team at Decision Resources Group, primarily focusing on psoriasis.

Prior to joining DRG, Yingdee was an analyst at Citeline, where he analyzed data on oncology clinical trials progression.  He was also a business development intern at the Massachusetts General Hospital Research Ventures and Licensing office, where he performed market research to look for invention licensing opportunities.  Yingdee received his Ph.D. in cell biology from the University of Massachusetts Medical School, and a B.S. in biology from the University of Pittsburgh at Greensburg.

Related Reports

Psoriasis - Geographic Focus: China - Psoriasis|China In-Depth|China

Psoriasis is an incurable chronic skin condition known to affect more than 8 million people in China. China’s psoriasis market has grown significantly over the last few years owing to the gro...

View Details

Psoriasis - Landscape & Forecast - Disease Landscape & Forecast

The psoriasis therapy market is becoming increasingly lucrative owing to the growing number of approved biologics. Although TNF-alpha inhibitors continue...

View Details

Psoriasis - Emerging Therapies - Skyrizi Launch Tracking Wave 3 (US)

In the past decade, the TNF-α inhibitors Humira (AbbVie) and Enbrel (Amgen) and the IL-12/23 inhibitor Stelara (Jan...

View Details

Psoriasis - Current Treatment - Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis Adult Psoriasis 2020 – Main Report Dashboard (US)

The adult psoriasis market has become increasingly lucrative owing to the growing use of biologics in the moderate to severe population, which cannot be adequately controlled with conventional syst...

View Details